Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.

Jurjen Versluis,Wael Saber,Harrison K Tsai,Christopher J Gibson,Laura W Dillon,Asmita Mishra,Joseph McGuirk,Richard T Maziarz,Peter Westervelt,Pranay Hegde,Devdeep Mukherjee,Michael J Martens,Brent Logan,Mary Horowitz,Christopher S Hourigan,Ryotaro Nakamura,Corey Cutler,R Coleman Lindsley

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 0|浏览38

暂无评分

摘要

HCT improved OS compared with non-HCT treatment in patients with mutations irrespective of allelic status. Patients with IPSS-M very high risk without a mutation had favorable outcomes when a donor was available.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要